関節の健康に対するEloctaの長期的な有効性を評価するための48か月の研究 (A-MORE)
関節の健康に対する Elocta の長期的な有効性を評価するための 48 か月にわたる多施設観察研究
This is a 48-month observational, prospective, multicentre study. The overall aim of the study is to evaluate the long-term effectiveness of Elocta treatment on joint health in patients treated prophylactically with Elocta in a real-world setting.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Haemophilia A is a rare genetic disorder estimated to occur in one out of 10,000 live births, characterized by a deficiency in coagulation factor VIII causing impaired haemostasis and prolonged bleeding episodes. Moderate haemophilia, defined as < 5%, and severe haemophilia, defined as < 1% of normal factor VIII activity result in frequent and spontaneous bleeds into muscles and joints, commonly the elbows, knees, and ankles. Bleeding into joints can cause acute pain and swelling and can result in reduced joint range of motion, long-term cartilage damage and debilitating haemophilic arthropathy. Early use of prophylaxis with factor VIII replacement is recommended following diagnosis of haemophilia A to maintain joint health and prevent joint destruction. However, despite the use of prophylaxis many patients still experience joint bleeds which may lead to joint deterioration over time. The risk of joint bleeds increases with the amount of time spent below certain FVIII trough levels, e.g. 1, 3 or 5 IU/dL. Thus, there is probably a relation between the intensity of the prophylactic treatment regimen and joint health. Elocta is an extended half-life rFVIII product (EHL rFVIII), with a slower clearance as compared to conventional FVIII products. Treatment with Elocta will therefore provide the treater with a greater flexibility for individualizing prophylaxis as compared to conventional FVIII. Higher trough levels can be reached with Elocta without increasing factor usage or injection frequency. The treater can instead choose to reduce the injection frequency or the factor consumption without lowering trough levels.
Patients may limit their physical activities due to fear of bleeding if they are unaware of their current FVIII level. Patient apps and wearables are now available which allow patients to view their predicted FVIII levels, and capture health-related data (such as bleedings, pain, well-being, physical activity levels etc.). This data can be shared with the treating physician supporting the planning to individualize the patient's factor treatment based on current lifestyle, health status and physical activity levels. Florio, a certified medical device used as part of routine clinical practice, is such an app, and the data output and patient feedback on their activity levels and sense of protection while using Florio will be analysed as exploratory objectives in this study.
The main purpose of this study is to evaluate the effectiveness of Elocta on joint health over a long observation period (48 months). The study will also explore the influence on long term joint health of different Elocta prophylaxis regimens leading to different trough levels and if the extent of patients' physical activity levels can be associated with predicted FVIII levels.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
-
Canterbury、イギリス
- East Kent Hospitals University NHS Foundation Trust, Kent Haemophilia and Thrombosis Centre, Kent and Canterbury Hospital
-
London、イギリス
- Great Ormond Street Hospital, Royal London Hospital for Integrated Medicine
-
-
-
-
-
Bari、イタリア
- University of Bari Aldo Moro (Centro Emofilia Policlinico - Pediatria U.O.)
-
Cesena、イタリア
- AUSL Romagna Centro Emofilia U.O.C., Medicina Trasfusionale Dipartimento Patologia, Clinica Ospedale M. Bufalini
-
Genova、イタリア
- Giannina Gaslini Institute
-
Milan、イタリア
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
-
Parma、イタリア
- University Hospital of Parma, AOUP, Haemophilia Center
-
Rome、イタリア
- Uo Malattie Emorragiche e Trombotiche Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Universitá Catolica del Sacro Coure
-
Torino、イタリア
- Azienda Ospedaliera Città della Salute e della Scienza di Torino Regina Margherita
-
-
-
-
-
Tallinn、エストニア
- Lastehaigla, Tallinn (Tallinn Children´s Hospital)
-
Tallinn、エストニア
- The North Estonia Medical Centre Hematoloogiakeskus, Regionalhaigla
-
-
-
-
-
Muscat、オマーン
- The Royal Hospital
-
-
-
-
-
Groningen、オランダ
- University Medical Center Groningen/UMCG
-
-
-
-
-
Thessaloniki、ギリシャ
- Ippokrateio Hospital Thessaloniki (adult department)
-
Thessaloniki、ギリシャ
- Ippokrateio Hospital Thessaloniki (pediatric department)
-
-
-
-
-
Riyadh、サウジアラビア
- Dr Suliman Al Habib Hospital Riyadh
-
Riyadh、サウジアラビア
- King Faisal Specialised Hospital, KFSH Riyadh, Children
-
Riyadh、サウジアラビア
- King Faisal Specialist Hospital KFSH, Adults
-
Riyadh、サウジアラビア
- Riyadh Military Hospital (P.S.M.C)
-
-
-
-
-
Bern、スイス
- Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor Inselspital
-
Lausanne、スイス
- Service et Laboratoire central d'hématologie, Adults
-
Sankt Gallen、スイス
- Zentrum für Labormedizin
-
Zurich、スイス
- Universitätsspital Zürich Klinik für Medizinische Onkologie und Hämatologie
-
-
-
-
-
Gothenburg、スウェーデン
- Hematologimottagning Sahlgrenska
-
Malmö、スウェーデン
- Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital Malmö
-
-
-
-
-
Barcelona、スペイン
- Sant Johan De Deu
-
Barcelona、スペイン
- Hospital de la Santa Creu i Sant Pau
-
Barcelona、スペイン
- Hospital Vall d'Hebron
-
Cruces、スペイン
- Hospital Universitario Cruces
-
Donostia / San Sebastian、スペイン
- Hospital Universitario Donostia
-
Murcia、スペイン
- Hospital Virgen de la Arrixaca
-
Málaga、スペイン
- Hospital Universitario Carlos Haya
-
Navarro、スペイン
- Complejo Hospitalario de Navarra
-
Oviedo、スペイン
- Hospital Universitario Central de Asturias (HUCA)
-
Palma de Mallorca、スペイン
- Hospital Universitario Son Espases
-
Seville、スペイン
- Hospital Universitario Virgen del Rocío
-
Vigo、スペイン
- Hospital Alvaro Cunqueiro
-
-
-
-
-
Ljubljana、スロベニア
- University Medical Centre Ljubljana Division of Paediatrics
-
-
-
-
-
Brno、チェコ
- University Hospital Brno
-
Ostrava、チェコ
- University Hospital Ostrava
-
Prague、チェコ
- Dept. of Pediatric Haematology and Oncology, University Hospital Motol
-
-
-
-
-
Berlin、ドイツ
- Charité-Universitätsmedizin Berlin Campus Virchow Klinikum
-
Bonn、ドイツ
- Universitätsklinikum Bonn AöR, Institut für Experimentelle Hämatologie und Transfusionsmedizin
-
Frankfurt、ドイツ
- Hämostaseologie/Hämophiliezentrum, Medizinische Klinik 2 Institut für Transfusionsmedizin, Universitätsklinikum
-
Frankfurt、ドイツ
- Universitätsklinikum Frankfurt - Klinik für Kinder- und Jugendmedizin
-
Hamburg、ドイツ
- Universitätsklinikum Hamburg-Eppendorf (UKE)
-
Hanover、ドイツ
- Medizinische Hochschule Hannover
-
Hanover、ドイツ
- Werlhof-Institut für Hämostaseologie GmbH
-
Heidelberg、ドイツ
- SRH-Klinikum Heidelberg
-
Mörfelden-Walldorf、ドイツ
- HZRM Hämöphilie Zentrum Rhein Main
-
München、ドイツ
- Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital am Universitätsklinikum München
-
-
-
-
-
Helsinki、フィンランド
- Helsinki University Central Hospital, New Children Hospital
-
Turku、フィンランド
- Turku University Central Hospital, Paediatric and adolescent haematology and oncology clinic
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients diagnosed with haemophilia A regardless of severity, of any gender and age, on factor treatment with Elocta according to usual clinical practice.
説明
Inclusion Criteria:
- Provided signed and dated informed consent by the patient, or the patient's legally authorized representative(s) for patients under the legal age, before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations
- Have a diagnosis of haemophilia A
- At enrolment on prophylactic treatment with Elocta, independent of participation in the study
Exclusion Criteria:
- Enrolment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
- Presence of factor VIII antibodies (inhibitors) (≥0.60 Bethesda Unit [BU]/mL) at the latest available inhibitor test
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Hemophilia A patients
All patients diagnosed with haemophilia A regardless of severity, on factor treatment with Elocta according to usual clinical practice. |
Extended half-life factor VIII product
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Joint health: Target joint development
時間枠:48 months
|
Number of target joints |
48 months
|
|
Joint health: Target joint resolution
時間枠:48 months
|
Number of resolved target joints |
48 months
|
|
Joint health: Target joint recurrence
時間枠:48 months
|
Number of recurring target joints |
48 months
|
|
Joint health: Annualised joint bleeding rate (AJBR) for treated bleeds
時間枠:48 months
|
Number of joint bleeding events per year, for treated bleeds |
48 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Disease Activity (hypertrophic synovium) and Disease Damage (Cartilage or Bone) scores for elbows, knees and ankles
時間枠:48 months
|
The Haemophilia Early Arthropathy Detection with UltraSound (HEAD-US) protocol will be used. The total score represents the sum of item scores for abnormalities detected. Its values range from 0 (minimum) to 8 (maximum). A higher score indicates a worse outcome. |
48 months
|
|
Global Gait Score, and/or joint score items for elbows, knees and ankles.
時間枠:48 months
|
The Haemophilia Joint Health Score (HJHS) system will be used. Global Gait Score, and/or Joint score items (swelling, duration of swelling, muscle atrophy, axial alignment, crepitus on motion, flexion loss, instability, extension loss, joint pain, strength, gait) for elbows, knees and ankles. The minimum score per joint is 0, the maximum score is 20. The overall total joint score (range 0-120) is the sum of the 6 six index joint (elbows, knees and ankles) scores. A higher score indicates a worse outcome. |
48 months
|
|
Joint and physical evaluation for elbows, knees and ankles.
時間枠:48 months
|
The WFH Physical Examination Score (AKA Gilbert Score) will be used. Joint evaluation (pain, bleeding, physical examination and radiologic evaluation) and physical evaluation (swelling, muscle atrophy, axial deformity, crepitus on motion, range of motion, flexion contracture, and instability). A higher score indicates a worse outcome. |
48 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for treated bleeds
時間枠:48 months
|
Number of bleeding events per year, for treated bleeds |
48 months
|
|
Effectiveness of Elocta: Annualised bleeding rate (ABR) for all bleeds
時間枠:48 months
|
Number of bleeding events per year, for all bleeds |
48 months
|
|
Effectiveness of Elocta: Occurrence of zero (0) joint bleeds
時間枠:48 months
|
Percentage (%) of study population with zero (0) joint bleeds |
48 months
|
|
Effectiveness of Elocta: Work productivity and impairment
時間枠:48 months
|
Assessed by WPAI-SHP questionnaire |
48 months
|
|
Effectiveness of Elocta: Quality of Life
時間枠:48 months
|
Assessed by Haemo-QoL/Haem-A-QoL questionnaire |
48 months
|
|
Effectiveness of Elocta: Physical activity level
時間枠:48 months
|
Assessed by the Saltin-Grimby scale |
48 months
|
|
Effectiveness of Elocta: Quality of Life
時間枠:48 months
|
Assessed by EQ-5D-5L/EQ-5D-Y questionnaire |
48 months
|
|
Effectiveness of Elocta: Severity of joint health
時間枠:48 months
|
Assessed by Patient Global Impression of Severity of Joint Health questionnaire |
48 months
|
|
Effectiveness of Elocta: FVIII plasma levels
時間枠:48 months
|
Percentage (%) of FVIII plasma level |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
時間枠:48 months
|
Assessed by medication dose |
48 months
|
|
Effectiveness of Elocta: Usage of pain and anti-inflammatory medication
時間枠:48 months
|
Assessed by total number of exposure days per medication |
48 months
|
|
Usage of Elocta: Annualised injection frequency per subject
時間枠:48 months
|
Assessed by prescription |
48 months
|
|
Usage of Elocta: Annualised factor consumption per subject
時間枠:48 months
|
Assessed by prescription [IU/kg] |
48 months
|
|
Usage of Elocta: Adherence
時間枠:48 months
|
Investigator assessed (Percentage (%)) |
48 months
|
|
Exploratory Objective
時間枠:48 months
|
Influence of different Elocta prophylaxis regimens on long term joint health |
48 months
|
|
Exploratory Objective: Impact of florio HAEMO on patients' sense of protection and their activity level
時間枠:48 months
|
Results from questionnaire on impact of florio HAEMO tools on patients' sense of protection and their activity level |
48 months
|
|
Exploratory Objective: Explore adherence to prescribed treatment regimen
時間枠:48 months
|
florio HAEMO captured treatment adherence scores |
48 months
|
|
Exploratory Objective: Explore relationship between predicted FVIII levels and physical activity
時間枠:48 months
|
florio HAEMO captured predicted FVIII levels, florio HAEMO captured physical activity (type, duration, heart rate and steps) |
48 months
|
|
Exploratory Objective: Explore timing of bleeds in relation to predicted FVIII levels and physical activity
時間枠:48 months
|
florio HAEMO captured bleed data (timing, location, cause, treated/untreated), florio HAEMO captured injection data (time, dose), florio HAEMO captured predicted FVIII levels |
48 months
|
|
Exploratory Objective: Explore the use of Florio to characterise pain and well-being
時間枠:48 months
|
florio HAEMO captured pain data (time, location, cause, intensity), florio HAEMO captured well-being data |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Target joint development, resolution and recurrence |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Annualised joint bleeding rate (AJBR) for treated bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Ultrasound (HEAD-US) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Clinical joint scoring (HJHS) |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Annualised bleeding rate (ABR) (based on bleeding episodes assessed according to local practice) for all bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Occurrence of zero (0) joint bleeds |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Quality of Life assessed by Haemo-QoL/Haem-A-QoL |
48 months
|
|
Exploratory Objective: Influence of different Elocta prophylaxis regimens on long term joint health
時間枠:48 months
|
Physical activity level assessed by the Saltin-Grimby scale |
48 months
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Study Physician、Swedish Orphan Biovitrum
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- Sobi.Elocta-005
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。